Business
Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting
A retrospective cohort study of claims data demonstrated that following hospital discharge, patients adherent to YUPELRI experienced significantly fewer, and
About this update from Theravance Biopharma, Inc.
[{"type":"text","content":"\n A retrospective cohort study of claims data demonstrated that following hospital discharge, patients adherent to YUPELRI experienced significantly fewer, and less severe, exacerbations and had significantly lower healthcare costs than non-adherent patients\n Post-hoc analyses of a Phase 3 safety study showed that patients taking YUPELRI had significantly lower incidence of moderate-to-severe acute exacerbations, and overall, less severe exacerbations, than patients taking tiotropium\n \n \n DUBLIN, Oct. 14, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (\"Theravance Biopharma\" or the \"Company\") (NASDAQ: TBPH), today announced that it will be presenting two rapid-fire presentations at CHEST 2025, the annual meeting of the American College of Chest Physicians taking place from October 19-22, 2025, in Chicago, IL.\n \n \n \n \n \n \n \n \"We are pleased to share new analyses on YUPELRI at the upcoming CHEST Annual Meeting. The findings of the retrospective database analysis of claims data evaluating exacerbations in the 3 months following hospital discharge demonstrates that adherent patients to YUPELRI had significantly fewer exacerbations, and particularly less severe ones, compared to non-adherent patients,\" commented Antonio Anzueto, M.D., Professor of Medicine, Pulmonary/Critical Section, University of Texas, Health San Antonio. \"The analysis not only showed that exacerbations were lower in adherent patients, but also their healthcare-related use and costs were significantly lower, highlighting the dual benefit of YUPELRI on patient outcomes. We are also presenting additional insights from the post-hoc analyses of the 52-week Phase 3 safety study highlighted that the YUPELRI exacerbation profile over 1 year is at least as effective as tiotropium. Taken together, the new analyses further strengthen the already compelling evidence for YUPELRI's use as a once-daily nebulized maintenance treatment for patients with COPD.\"\n Details on the presentations are as follows:\n \n Title: Exacerbation Rates in COPD Patients: A Retrospective Analysis of the Nebulized Once Daily Long-Acting Muscarinic Antagonist Revefenacin in a 52-Week Safety StudyPresenter: Edmund J Moran, Ph.D., Theravance BiopharmaDate and time: October 21, 2025; 10:56 – 11:00 AM CT; Emerging Trends in COPD\n \n Title: Adherence to Revefenacin Associated with ...